Aaron Cranston

Institute for Advanced Learning and Research — United States

Medicine · Health Sciences

19h-index3.7kcitations88works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(29), Cancer-related Molecular Pathways(17), DNA Repair Mechanisms(15), Genetic factors in colorectal cancer(9), RNA modifications and cancer(9)

Publications88 total

A Self-Supervised Paradigm for Heterophilic Graph Representation Learning
SSRN Electronic Journal·2026Open Access
Hyper-Spectral: Adaptive Frequency Filtering for Heterophilic Hypergraph Neural Networks
SSRN Electronic Journal·2026Open Access
Abstract LB229: ALM-401: A first-in-class next generation bispecific ADC configured to deliver superior efficacy in selected solid tumor indications
Cancer Research·2025· 1 cited
Abstract LB045: Exploiting biparatopic binding to deliver novel, differentiated ALPP/ALPPL2 targeting protein drug conjugates
Cancer Research·2024· 2 cited
Abstract LB041: Exploiting a multi-center pre-clinical mouse PDX mini trial to identify new clinical opportunities for protein-drug conjugates (PDCs) targeting ROR1
Cancer Research·2024
USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF
Clinical and Translational Medicine·2024· 11 citedOpen Access
Abstract LB011: Development of novel protein drug conjugates (PDCs) for the selective targeting of ALPP/ALPPL2 expressing tumors
Cancer Research·2023
Abstract LB022: A novel first-in-class USP19 inhibitor for the treatment of cancer-induced muscle atrophy
Cancer Research·2023· 2 cited
Supplementary Figure Legends 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Figures 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Figure Legends 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Figures 1-10 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Data from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Tables 1-2 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Data from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Tables 1-2 from Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i>-Mutated Mouse Mammary Tumors
2023Open Access
Supplementary Figure S1 from Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
2023Open Access
Data from Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
2023Open Access
Supplementary Materials and Methods, Supplementary Tables 1 through 3, and Supplementary Figure 1 from The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
2023Open Access
Data from Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Alan Lau(11), Mark J. O’Connor(11), Niall M.B. Martin(11), Richard Fishel(7), Charlotte Knights(6), Mark Wappett(6), Graeme C.M. Smith(5), Bruce A.J. Ponder(5), Xavier Jacq(5), Tim J. Harrison(5), Graham Cotton(4), Paul Trumper(4), Chiara Saladino(4), Aidan McCann(4), Andrew J. McKenzie(4), Phil Mallinder(4), Anna M. Grabowska(4), Rajendra Kumari(4), Sven Rottenberg(3), Janneke E. Jaspers(3)